443 related articles for article (PubMed ID: 12888593)
1. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
4. High purity amphotericin B.
Cleary JD; Chapman SW; Swiatlo E; Kramer R
J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
8. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
10. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B.
Oda MN; Hargreaves PL; Beckstead JA; Redmond KA; van Antwerpen R; Ryan RO
J Lipid Res; 2006 Feb; 47(2):260-7. PubMed ID: 16314670
[TBL] [Abstract][Full Text] [Related]
11. Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.
Alvarez C; Andes DR; Kang JY; Krug C; Kwon GS
Pharm Res; 2017 May; 34(5):1115-1124. PubMed ID: 28205003
[TBL] [Abstract][Full Text] [Related]
12. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans.
Brime B; Molero G; Frutos P; Frutos G
Eur J Pharm Sci; 2004 Aug; 22(5):451-8. PubMed ID: 15265515
[TBL] [Abstract][Full Text] [Related]
13. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
15. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
16. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
[TBL] [Abstract][Full Text] [Related]
17. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
Souza LC; Campa A
J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
